News

Inoviem Scientific leverages two proprietary technologies to offer the pharmaceutical industry access at all stages of drug development. Inoviem supports all stages of drug development, from drug discovery

Equipped to ensure cost-effective, high-quality production of API using microbial expression systems, Enteris BioPharma offers pharmaceutical companies a full array of services to meet their manufacturing needs, from

RAK Pharmaceuticals, based in Bangladesh, was a subsidiary of RAK Ceramics and produces a variety of industry compliant tablets, capsules and syrups that are fit quality wise to

PF582 is Pfenex’s biosimilar candidate to Genentech’s Lucentis (ranibizumab injection). As part of the deal, Pfenex will receive an upfront payment of $51m once the collaboration receives antitrust

The new agreement builds on an existing collaboration between the two parties, which resulted in a successful launch of Emtrix in Italy as well as the expansion to

The post-doctoral diabetes research program will be fully funded by Novo Nordisk. In this program, a total of 12 post-doctoral researchers will be offered a three-year grant to

The agreement will give Boehringer access to VTU’s yield-enhancing Pichia pastoris expression platform to develop and manufacture therapeutic proteins. The platform is based on VTU’s AOX1 promoter libraries

The Janssen decision to advance ADU-741 toward clinical trials was based on preclinical data generated in the first eight months of the collaboration. This accomplishment triggered a milestone

ADS-5102 is initially being developed by Adamas for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. ADS-5102, an investigational agent, is a long-acting, extended-release capsule